RHP 5.54MTRN 4.28PSMT 0ESLOY 0MSFT -8.48META -4.53HLPR.TO 0VDY.TO -0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

24.04
-0.68 (2.75%)
as of Jun 24, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges including a patent cliff and the aftermath of over-earning during the COVID-19 pandemic. The company has made efforts to bolster its drug pipeline through acquisitions, such as Seagen, but many experts express concerns about the lack of earnings momentum and blockbusters to drive growth. While the stock offers an attractive dividend yield (around 6-7%), there is a prevailing sentiment around its long-term growth prospects as reliance on cost-cutting and strategic acquisitions seems insufficient. Analysts highlight the need for a new growth catalyst, particularly in oncology, to reassure investors as the dividend yield may be at risk if substantial progress with new drugs is not achieved. Overall, patience is emphasized by many experts, with a hope that the stock will eventually perform better amid potential improvements in government policies and market conditions.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
AstraZeneca, AZN
HOLD

Pfizer Inc(PFE)

Jul 07, 2009
Reflects all the bad news that Lipitor will be going going off patent in a couple of years and its drug pipeline is absolutely barren. In the meantime you get paid 6.5%. Pretty cheap.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$14.59

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 06, 2009
Thinks the pharmaceutical sector will start to do quite well in the next 2 years. It is so negative now in terms of what the government wants to do but historically they have never been able to cut the price of drugs. You are getting 5% to wait.
Photo of Kevin O'LearyKevin O'Leary
Owned
Unlock Rating
$14.57

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 12, 2009
Not a fan of big cap pharma and hasn't been for some time. One of the most difficult business models to operate. Regulatory issues are so difficult to overcome between patent expiries and increasingly stringent health regulations and registration processes. (See Top Picks.)
Photo of Charles LannonCharles Lannon
No
Unlock Rating
$14.76

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jun 04, 2009
The major pharmaceuticals are not on his top list. Bioteches are where you are going to see innovations. They are the ones coming out with the new drugs and have a better pipeline.
Photo of Matthew McCallMatthew McCall
No
Unlock Rating
$14.64

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 06, 2009
Just doesn't seem to be up to right itself. Spinning off a lot of cash but its size limits it from growing.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$13.91

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 14, 2009
Getting killed by generics. They get sued when they hurt people. Government won't stand up for them when generics can provide health care at a fraction of the price. Prefer TEVA-O
Photo of David BaskinDavid Baskin
No
Unlock Rating
$13.34

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 31, 2009
Has been a difficult stock. Could improve from here however there will be other opportunities in this space you could get more juice from.
Photo of Brett HrybBrett Hryb
Owned
Unlock Rating
$13.62

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 30, 2009
(A Top Pick April 10/08. Down 27.8%.) Paired with Teva (TEVA-Q) as his generic company. Down a little because of their intention to purchase Wyath. Cut their dividend but still gives a healthy yield. Good defensive place.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$13.70

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 26, 2009
Made a good acquisition of Wyeth. Have created value in previous acquisitions. Cut the dividend while making the deal so the stock price fell. This made a lot of sense. The big issue is whether this will fill a hole in their product line. Reasonable dividend and very good balance sheet.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$14.38

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 18, 2009
A former glory growth stock. A lot of healthcare products and there is the issue of aging in America but that is offset by many of their expensive premier drugs going generic. Just cut their dividends. Would prefer other pharmaceutical stocks.
Photo of David AbellaDavid Abella
No
Unlock Rating
$14.25

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Feb 24, 2009
(A Top Pick Feb 27/08. Down 40%.)
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$13.59

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 13, 2009
Cut the dividend in order to preserve cash to make acquisitions even though their balance sheets is fortress like. Lipitor is coming off patent in a couple of years. Stock has been very disappointing. A "show me" stock.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$14.58

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 09, 2009
(Market Call Minute.) Just completing an acquisition.
Photo of Brett HrybBrett HrybUnlock Rating
$14.71

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 06, 2009
At this price it is probably near a low. Made a big acquisition that is scaring everybody. Can't see a lot of downside from here.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$14.84

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jan 30, 2009
Made a huge bet with their acquisition of Wyeth and the patents are running off. If it doesn't work out they are going to have some very difficult times.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$14.58

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Showing 481 to 495 of 883 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -8.48$365.46
PPL.TO -0.83$66.15
CVE.TO -1.49$35.09
TOU.TO -0.68$59.86
GOOG -1.04$345.04

Today's Top Picks

RHP 5.54$129.77
MTRN 4.28$269.62
PSMT 0$
ESLOY 0$95.66
MSFT -8.48$365.46

Popular Articles

Latest Sell Signals

ATD.TO 1.89$93.76
ITB 5.99$103.32
GLD -11.4$365.92
MU -3.26$1048.51
MU -3.26$1048.51

Most Recent Experts

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically